Antithrombotic effects of aspirin based on PLA1/A2 glycoprotein IIIa polymorphism in patients with coronary artery disease.
OBJECTIVE
The diallelic glycoprotein IIIa polymorphism P1A1/A2 was attributed to be an inherited risk factor for coronary events. Whether this polymorphism affects response to aspirin in patients with coronary artery disease is not known.


METHODS
We assessed thrombin generation (prothrombin fragment F1+2) in consecutive blood samples collected from bleeding-time wounds in 28 men with coronary artery disease; P1A2 carriers, n=9; P1A1/A1, n=19. Thrombin generation and bleeding time were measured before and after 2 weeks of aspirin 300 mg/day.


RESULTS
Aspirin-depressed thrombin generation in A1 homozygotes (p=0.04), but not in A2 carriers. Bleeding time after aspirin was also prolonged in A1 subjects only (p=0.02).


CONCLUSIONS
Genotyping for glycoprotein IIIa polymorphism might be helpful in predicting antithrombotic action of aspirin in secondary prevention of coronary artery disease.
Dropinski
Jerzy
J
Department of Medicine, Jagiellonian University School of Medicine, Cracow, Poland, 31-066 Krakow, ul. Skawinska 8, Poland.
Musial
Jacek
J
Sanak
Marek
M
Wegrzyn
Wojciech
W
Nizankowski
Rafal
R
Szczeklik
Andrew
A